CAR T cell therapy is one of the most promising new cancer treatments to emerge in recent years. It involves removing a patient's own immune T cells and engineering them to recognize specific targets ...

Findings indicate that altering glucose metabolism in T cells boosts their therapeutic potential against melanoma, paving the ...

Fintel reports that on January 31, 2025, Canaccord Genuity downgraded their outlook for Intra-Cellular Therapies ...

In a report released on January 27, Jessica Fye from J.P. Morgan maintained a Buy rating on Intra-Cellular Therapies (ITCI – Research Report), ...

We recently compiled a list of the Why These 15 Stocks Are Skyrocketing in 2025. In this article, we are going to take a look ...

On the company’s Q4 earnings call where an eyepopping $88.8 billion in full-year sales were revealed, leaders shifted focus ...

Fintel reports that on January 22, 2025, RBC Capital downgraded their outlook for Intra-Cellular Therapies (NasdaqGS:ITCI) ...

The New Jersey-based drugmaker expects 2025 sales of between $90.9 billion and $91.7 billion, and to earn between $10.75 and ...

Intra-Cellular Therapies, Inc. recently disclosed its entry into an Agreement and Plan of Merger with Johnson & Johnson, a New Jersey corporation, along with Fleming Merger Sub, Inc., a Delaware ...

T-cell therapy, originally developed for haematological malignancies, has recently emerged as a promising therapy for ...